Article
Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study.
BMC cancer - 14 Oct 2015
Soda Hitoshi, Maeda Hiromichi, Hasegawa Junichi, Takahashi Takao, Hazama Shoichi, Fukunaga Mutsumi, Kono Emiko, Kotaka Masahito, Sakamoto Junichi, Nagata Naoki, Oba Koji, Mishima Hideyuki
Abstract excerpt
BACKGROUND: The clinical benefit of cetuximab combined with oxaliplatin-based chemotherapy remains under debate. The aim of the present multicenter open-label Phase II study was to explore the efficacy and safety of biweekly administration of cetuximab and mFOLFOX-6 or XELOX as first-line chemotherapy in patients with metastatic colorectal cancer. METHODS: Sixty-two patients with previously untreated KRAS/BRAF...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.